BION BB Biotech AG Ord
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domiciled in Switzerland.…
Industry Peers
Capital MarketsKey Statistics
About BB Biotech AG Ord (SWX: BION)
›
BB Biotech AG Ord (SWX: BION) is listed on the SIX Swiss Exchange, where its shares trade in CHF. It belongs to the Capital Markets industry, part of the Financial Services sector, and reports about 10 employees.
The shares were at 52.60 CHF on 19 November 2026, up 32.9% over 52 weeks. Its 52-week range is 41.05 CHF to 56.90 CHF: the price is 7.6% below the high and 28.1% above the low.
At a market capitalisation of 2.90B CHF, it trades at 2.7 times trailing earnings. The median trailing P/E of its 19 largest Capital Markets peers is 15.5, a discount of 83% for BION. It pays a dividend yielding 4.26% (it pays out 12% of its earnings), against a median of 1.81% among the dividend payers in that peer group.
BB Biotech AG Ord reports return on equity of 20.8%, an operating margin of 96.2% and revenue down 60.8% year over year.
It holds more cash than debt, a net cash position of 3.30B CHF. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. One analyst covers the stock, with an average rating of Buy; their mean price target of 73.00 CHF is 38.8% above the current price. The next earnings report is expected on 19 February 2027.